Side-by-side comparison of AI visibility scores, market position, and capabilities
Tempur Sealy (NYSE: TPX) world's largest bedding manufacturer with NASA-derived TEMPUR memory foam at ~$4.5B revenue; premium $2,000-5,000+ mattresses competing with Sleep Number and Purple for the premium sleep products market.
Tempur-Pedic is the premium memory foam mattress brand of Tempur Sealy International, Inc. (NYSE: TPX) — a Lexington, Kentucky-based publicly listed sleep products company that merged Tempur-Pedic International and Sealy Corporation in 2013 — producing TEMPUR-material memory foam mattresses, adjustable foundations, and sleep accessories using proprietary viscoelastic foam originally developed by NASA for spacecraft seat cushioning. Tempur Sealy International generated approximately $4.5 billion in net sales in fiscal year 2024, operating the Tempur-Pedic premium brand alongside Sealy (innerspring and hybrid mattresses across multiple tiers), Stearns & Foster (luxury handcrafted mattresses), and Cocoon by Sealy (direct-to-consumer compressed mattress), collectively positioning Tempur Sealy as the world's largest bedding manufacturer.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.